Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasm Metastasis 36Leukemia, Myeloid, Acute 34Multiple Myeloma 27Lymphoma 23Breast Neoplasms 19Pancreatic Neoplasms 18Prostatic Neoplasms 17Colorectal Neoplasms 17Burkitt Lymphoma 17Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Myelodysplastic Syndromes 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Melanoma 11Lung Neoplasms 11Sarcoma 10Lymphoma, T-Cell 9Glioma 9Carcinoma, Non-Small-Cell Lung 9Neuroblastoma 8Neoplasms 8Leukemia, Biphenotypic, Acute 8Fallopian Tube Neoplasms 8Carcinoma, Renal Cell 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Endometrial Neoplasms 7

Interventions

Gemcitabine 8Cisplatin 8pembrolizumab 4durvalumab 4Specimen Handling 3Platinum 3Oxaliplatin 3Leucovorin 31,2-diaminocyclohexaneplatinum II citrate 3fludarabine 2Taxes 2Nivolumab 2Magnetic Resonance Spectroscopy 2Folfox protocol 2Fluorouracil 2Cyclophosphamide 2Biopsy 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zanidatamab 1trastuzumab deruxtecan 1tivozanib 1peposertib 1guadecitabine 1dehydroftorafur 1binimetinib 1avelumab 1atezolizumab 1Trastuzumab 1S 1 (combination) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × Biopsy × 90 days × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT05564403 2026-05-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡